ATXI OTC
Avenue Therapeutics, Inc.
1W: -18.5%
1M: -28.5%
3M: +23.5%
YTD: -40.6%
1Y: -43.4%
3Y: -99.2%
5Y: -100.0%
$0.41
+0.05 (+13.22%)
Weekly Expected Move ±37.9%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$1M
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$3M
+72.7% ▲
Net Income
-$3M
+75.0% ▲
EPS (Diluted)
$-0.93
-3.3% ▼
EBITDA
-$3M
+73.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | 0.0% |
| R&D Expenses | $1M | $3M | $10M | $7M | $1M |
| SG&A Expenses | $2M | $5M | $4M | $5M | $4M |
| Operating Expenses | $4M | $8M | $15M | $11M | $5M |
| Operating Income | -$4M | -$8M | -$15M | -$11M | -$3M |
| Operating Margin | — | — | — | — | -219.6% |
| Interest Expense | $0 | $1M | $0 | $0 | $0 |
| Income Before Tax | -$4M | -$4M | -$10M | -$12M | -$3M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$4M | -$4M | -$10M | -$12M | -$3M |
| Net Margin | — | — | — | — | -207.2% |
| EPS (Diluted) | $-3.29 | $-121.91 | $-73.48 | $-0.90 | $-0.93 |
| EBITDA | $7K | -$2M | $4M | -$12M | -$3M |
| Shares Outstanding | 1M | 29135 | 141221 | 13M | 3M |